Camicinal

Camicinal is a motilin agonist for the treatment of gastroparesis.[1][2][3]

Camicinal
Clinical data
Other namesGSK962040
Identifiers
IUPAC name
  • 1-{4-[(3-Fluorophenyl)amino]-1-piperidinyl}-2-(4-{[(3S)-3-methyl-1-piperazinyl]methyl}phenyl)ethanone
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ECHA InfoCard100.158.139
Chemical and physical data
FormulaC25H33FN4O
Molar mass424.564 g·mol−1
3D model (JSmol)
SMILES
  • C[C@H]1CN(CCN1)CC2=CC=C(C=C2)CC(=O)N3CCC(CC3)NC4=CC(=CC=C4)F
InChI
  • InChI=1S/C25H33FN4O/c1-19-17-29(14-11-27-19)18-21-7-5-20(6-8-21)15-25(31)30-12-9-23(10-13-30)28-24-4-2-3-22(26)16-24/h2-8,16,19,23,27-28H,9-15,17-18H2,1H3/t19-/m0/s1
  • Key:RZKDEGZIFSJVNA-IBGZPJMESA-N

References
  1. Barshop K, Kuo B (January 2015). "The investigational drug camicinal for the treatment of gastroparesis". Expert Opinion on Investigational Drugs. 24 (1): 133–140. doi:10.1517/13543784.2015.975792. PMID 25341626. S2CID 25896703.
  2. Hobson R, Farmer AD, Dewit OE, O'Donnell M, Hacquoil K, Robertson D, et al. (November 2015). "The effects of camicinal, a novel motilin agonist, on gastro-esophageal function in healthy humans-a randomized placebo controlled trial". Neurogastroenterology and Motility. 27 (11): 1629–37. doi:10.1111/nmo.12663. PMID 26348542.
  3. Chapman MJ, Deane AM, O'Connor SL, Nguyen NQ, Fraser RJ, Richards DB, et al. (August 2016). "The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial". Critical Care. 20 (1): 232. doi:10.1186/s13054-016-1420-4. PMC 4967996. PMID 27476581.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.